Overview
Investors 4
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Flucas Ventures | flucasvc.com | |
| Jan 9, 2022 | RA Capital Management | racap.com |
| Adjuvant Capital | adjuvantcapital.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Aug 15, 2023 | Funding round | $70M | |
| Jan 7, 2022 | Series B round | $80M | |
| Nov 21, 2019 | Series A round | $12M |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 22, 2024 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results | Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring fu... |
| Aug 15, 2023 | AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock | |
| Sep 29, 2022 | NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million | Non-dilutive funding will drive synergies with existing epetraborole development program for NTM lung disease Award leverages AN2 Therapeutics expertise and commitment to address urgent unmet global health needs Work could help address U.S.... |
| Jan 7, 2022 | AN2 Therapeutics Closes $80M Series B Financing | AN2 Therapeutics, Inc., a Menlo Park, CA-based clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases, completed an $80m Series B redeemable convertible preferred stock f... |
| Nov 21, 2019 | AN2 Therapeutics Raises $12M in Series A Funding | AN2 Therapeutics, Inc., a Menlo Park, Calif.-based biopharmaceutical company focused on the research, development, and commercialization of novel medicines targeting infectious diseases, raised $12m in Series A financing. The round was led ... |
| Nov 21, 2019 | AN2 Therapeutics Secures $12M Series A | MENLO PARK, CA, AN2 Therapeutics today announced that it has raised $12 million in a Series A financing. >> Click here for more funding data on AN2 Therapeutics >> To export AN2 Therapeutics funding data to PDF and Excel, cl... |
| AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test | Economic concerns have halted or at least delayed the plans of many companies to go public, but one biotech is braving the financial tumult, raising $69 million from its IPO to fund a pivotal test of a novel antibiotic licensed from Pfizer.... |
Reviews 0
FAQ about AN2 Therapeutics
When was AN2 Therapeutics founded?
AN2 Therapeutics was founded in 2017.
How much funding has AN2 Therapeutics raised?
AN2 Therapeutics has raised $202M in total across 4 funding rounds.
What funding rounds has AN2 Therapeutics raised?
Parsers VC lists 4 funding rounds of AN2 Therapeutics, among them a funding round of $70M on Aug 15, 2023, a Series B round of $80M on Jan 7, 2022 and a Series A round of $12M on Nov 21, 2019.
Who has invested in AN2 Therapeutics?
Parsers VC lists 4 investors of AN2 Therapeutics, among them RA Capital Management, Flucas Ventures and Adjuvant Capital.
What has the press written about AN2 Therapeutics?
Parsers VC has collected 8 articles mentioning AN2 Therapeutics, among them “Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results” (Mar 22, 2024) and “AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock” (Aug 15, 2023).
Is AN2 Therapeutics still active?
Yes, AN2 Therapeutics is active; its latest activity on Parsers VC dates from Mar 9, 2026.